India Pushes Forward with Key Trade Deals with US and Australia

What Happens Next

• →Indian pharmaceutical and agri-tech firms gain preferential tariff access to Australian and US markets, enabling price competitiveness against established suppliers from China and the EU in those sectors.
• →Australian generic drug manufacturers and domestic agri-tech firms face margin compression as lower-cost Indian products enter under reduced tariffs, prompting industry groups to push for safeguard clauses or origin-of-manufacture requirements.
• →Completion of an India-US trade agreement creates a template for accelerated bilateral negotiations with other partners (UK, EU), increasing India's leverage in parallel trade discussions.

Near-term: Indian exporters in pharmaceuticals and agri-tech begin contract negotiations and supply chain positioning for Australian and US markets as deal terms are finalized, with early shipments under new frameworks expected within 3 months of ratification. Long-term: India leverages completed US and Australian trade agreements as precedent frameworks to negotiate preferential access with the EU and UK, structurally repositioning itself as a primary non-Chinese manufacturing exporter in the Indo-Pacific.